CEO Mark McKenna (Prometheus Biosciences)
Prometheus Bio is ready for its close-up shot, following a $130M round to back IBD drugs now headed to the clinic
A little over a year ago, Takeda lined up a deal to collaborate with a low-profile San Diego upstart called Prometheus Biosciences on a string …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
